key: cord-0942970-kt9jud9n
authors: Glenn, Dorey A.; Hegde, Anisha; Kotzen, Elizabeth; Walter, Emmanuel B.; Kshirsagar, Abhijit V.; Falk, Ronald; Mottl, Amy
title: Systematic review of safety and efficacy of COVID-19 vaccines in patients with kidney disease
date: 2021-02-09
journal: Kidney Int Rep
DOI: 10.1016/j.ekir.2021.02.011
sha: 796648724f1a4ad5442a21afbd22e73f074f3fcc
doc_id: 942970
cord_uid: kt9jud9n

nan

Chronic kidney disease (CKD) affects 37 million or 15% of the US population and 2 in every 1000

Americans are on dialysis or living with a kidney transplant 1 . In 2020 COVID-19 infection became the third leading cause of death for persons 45 through 84, and individuals with kidney disease are recognized as being at higher risk for severe complications from COVID-19 infection 2,S1 . While vaccination is a powerful and cost-effective method to reduce infection-related morbidity and mortality, vaccine efficacy has historically not been rigorously studied in individuals with CKD, and COVID-19 vaccine immunogenicity is largely unknown in this high-risk population. Numerous clinical trials of candidate COVID-19 vaccines have been undertaken; however, it is unknown whether results are generalizable to individuals living with kidney disease, in particular those on dialysis or receiving chronic immunosuppression for treatment of glomerulonephritis or kidney transplantation. We sought to systematically review registered COVID-19 vaccine clinical trials for inclusion of criteria relevant to individuals with kidney disease (Supplementary Methods).

As of December 6 th , 2020, we screened 342 registered COVID-19 vaccine clinical trials (142 from ClinicalTrials.gov S3 and 200 from the WHO Clinical Trial database S3 ). Excluded trials included: 118 duplicate trials, 52 trials repurposing non-COVID-19 vaccines (e.g. BCG vaccine), and 4 trials studying vaccination for non-primary prevention of COVID-19 ( Figure 1 ). Trial characteristics of the resulting 123 unique COVID-19 vaccine trials are displayed in Table 1 .

Any CKD was explicitly excluded from 16% of trials, 'serious renal disease' from 33% of trials, and left to 'investigator discretion' in an additional 46% of trials. Few studies used a specific eGFR threshold of ≥60 ml/min/1.73m 2 to determine eligibility (6%). In phase 3 trials specifically, 39.4% included patients with any or mild/moderate CKD, with the remaining 60.6% of trials leaving the window open for their exclusion. Individuals receiving immunosuppression for maintenance of a kidney transplant or treatment J o u r n a l P r e -p r o o f of an underlying glomerular disease were excluded from 78% of non-live attenuated trials and all liveattenuated trials (n=3). Exclusion was not explicit in the remaining trials. Similarly, individuals with an immunocompromising disease were excluded from 86% of trials, with the remaining trials having unclear or absent criteria for those with immunocompromising health conditions. In phase 3 trials, 93.5% excluded patients with immunocompromising conditions and 64.5% excluded those on any immunosuppression, and an additional 32.3% excluding any immunosuppression other than low dose (10-20mg/day) prednisone. Two recently published phase 3 trials of SARS-CoV-2 vaccines now in clinical use are illustrative of the lack of clarity and inclusion of patients with kidney disease. Pfizer's trial of BNT162b2 included participants with stable chronic medical conditions, however, only 0.7% of randomized subjects (n=256) had "renal disease"; a proportion well below the 15% CKD prevalence in the general population 3 . Moderna's trial of the mRNA-1273 vaccine also included participants with stable chronic medical conditions, but has not released data about the prevalence of participants with kidney disease 4 . Immunocompromised subjects were excluded from both trials. Of note, a recently announced phase 3 trial investigating Novavax's candidate vaccine, NVX-CoV2373, will not exclude prospective participants with stable CKD (NCT04611802), though those receiving chronic immunosupressants are excluded.

Our findings suggest that inclusion of patients with kidney disease in completed and ongoing COVID-19 vaccine studies remains low, with the majority of trials explicitly excluding individuals with "severe" or "chronic" kidney disease and those receiving immunosuppression. Few trials specify an eGFR cutoff or CKD stage below which individuals were excluded, leaving room for investigator discretion and lack of clarity for providers to counsel their patients. Our findings have several important implications. First, the low inclusion rates of patients with kidney disease continue to perpetuate the dearth of data on vaccine immunogenicity, efficacy, and safety in the kidney disease population. The Centers for Disease Control (CDC) recommends that individuals with high-risk medical conditions, including those with CKD and J o u r n a l P r e -p r o o f those immunocompromised from solid organ transplants, be prioritized for vaccination, without any data on COVID-19 vaccine efficacy in these populations 5 . Currently, trials are under way to study vaccine response in children who were excluded from the original studies and the same should occur for patients with CKD and/or immunosuppressed status. Second, the low rates of CKD inclusion in trials may further exacerbate disparities already pervasive in the pandemic. In the US, African-Americans and Latinos bear a disproportionate burden of both CKD and of mortality due to COVID-19 6 

In the United States, nearly 470,000 individuals receive maintenance dialysis, with the majority choosing in-center treatments rather than home therapies S7 . While there is little doubt that these patients should receive the COVID-19 vaccine, there may be concern about their effectiveness based on data on the durability of the antibody response from influenza vaccines S11 . Dialysis patients should be explicitly included in future clinical trials of COVID-19 vaccines. Furthermore, large dialysis organizations should work with the CDC to develop a monitoring plan for markers of immunogenicity (much like for hepatitis B antibody titers) and for COVID-19-related hospitalizations and mortality. Dialysis organizations already have routine laboratory and clinical evaluations in place, and to not make use of this infrastructure would be a lost opportunity.

In summary, to ensure maximal trust in and uptake of novel COVID-19 vaccines, clinical trials should be designed to explicitly evaluate the immunogenicity of COVID-19 vaccines in patients with kidney disease. A safety label for patients with kidney disease is insufficient. The nephrology community needs to take rapid action to implement antibody titer monitoring and vaccine immunogenicity studies in CKD patients, particularly those on dialysis, with autoimmune mediated kidney disease or receiving immunosuppressive medications. Without a timely and coordinated approach our patients will be left behind the general population in fighting the COVID-19 pandemic.

J o u r n a l P r e -p r o o f 

Chronic Kidney Disease in the United States

Estimated County-Level Prevalence of Selected Underlying Medical Conditions Associated with Increased Risk for Severe COVID-19 Illness -United States

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

The Advisory Committee on Immunization Practices' Updated Interim Recommendation for Allocation of COVID-19 Vaccine -United States

COVID-19 and Racial/Ethnic Disparities

Prophylactic vaccinations in chronic kidney disease: Current status. Hum Vaccines Immunother

Practical Guide to Vaccination in All Stages of CKD, Including Patients Treated by Dialysis or Kidney Transplantation

Detection of SARS-CoV-2 Antibodies in Kidney Transplant Recipients

The authors would like to acknowledge the support of Dr. Samantha Kaplan for her